Lipids, cardiovascular disease and atherosclerosis in systemic lupus erythematosus

Lupus. 2000;9(3):194-201. doi: 10.1191/096120300678828235.

Abstract

Systemic lupus erythematosus is commonly associated with early onset cardiovascular disease and is often associated with hyperlipidaemia. This review examines the evidence for an increased prevalence of both CHD and hyperlipidaemia in SLE and mechanisms by which autoimmunity in SLE could accelerate the progression of atheroma. It postulates how lipid lowering therapies used in cardiological disease might help reduce the incidence of CHD in SLE.

Publication types

  • Review

MeSH terms

  • Arteriosclerosis / etiology*
  • Arteriosclerosis / metabolism*
  • Autoantibodies / metabolism
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / etiology*
  • Cardiovascular Diseases / metabolism*
  • Endothelium, Vascular / physiopathology
  • Female
  • Humans
  • Hypolipidemic Agents / therapeutic use
  • Inflammation / complications
  • Insulin Resistance
  • Lipid Metabolism*
  • Lipoprotein(a) / metabolism
  • Lipoproteins / immunology
  • Lupus Erythematosus, Systemic / complications*
  • Lupus Erythematosus, Systemic / metabolism*
  • Lupus Nephritis / etiology
  • Risk Factors
  • Stroke / etiology

Substances

  • Autoantibodies
  • Hypolipidemic Agents
  • Lipoprotein(a)
  • Lipoproteins